US Markets

Regeneron Pharma posts quarterly profit on $228 mln gain

Credit: REUTERS/MIKE SEGAR

Regeneron Pharmaceuticals Inc reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.

Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.

Net income rose to $897.3 million, or $7.61 per share, in the second quarter ended June 30, from $193.1 million, or $1.68 per share, a year earlier.

Revenue rose to $1.95 billion from $1.58 billion.

(Reporting by Dania Nadeem and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More